1. Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report.
- Author
-
Yang, Yanping, Lin, Hai, Du, Zhonghua, Hu, Ruiping, Tang, Yang, Liang, Xinyue, Sun, Jingnan, and Tan, Yehui
- Subjects
- *
ACUTE myeloid leukemia , *PLATELET-derived growth factor receptors , *IMATINIB , *GENE rearrangement , *PROTEIN-tyrosine kinases , *PULMONARY eosinophilia - Abstract
The fusion product of FIP1-like-1 (FIP1L1) and platelet-derived growth factor receptor α (PDGFRA) gene rearrangement is a tyrosine kinase oncoprotein sensitive to imatinib. This gene rearrangement characterizes a novel clinico-biological class of myeloid and lymphoid neoplasms with eosinophilia and PDGFRA abnormalities. The DEK proto-oncogene (DEK) and nucleoporin 214 (NUP214) rearrangement is rare in patients with acute myeloid leukemia (AML); therefore, the coexistence of DEK-NUP214 and FIP1L1-PDGFRA rearrangements in patients with AML is extremely rare. The present study presents a rare relapse case of a patient with AML with DEK-NUP214 and FIP1L1-PDGFRA rearrangements, without marked eosinophilia in the peripheral blood or bone marrow. Low-dose imatinib monotherapy without intensive chemotherapy was used to achieve complete hematological remission. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF